- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Price not available for IHE:GR
Snapshot for Innexus Biotechnology Inc (IHE)
| Open: | - | Day's Range: | - | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 0.002 | 52wk Range: | - | 1-Yr Rtn: | - |
Key Statistics for IHE
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | - |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for IHE
No data available
Company Profile & Key Executives for IHE
InNexus Biotechnology Inc. is developing a new generation of monoclonal antibodies termed SuperAntibodies (SAT). The Company is exploiting SAT to generate second generation diagnostic and therapeutic antibodies. InNexus is focused on marketing the SAT to the pharmaceutical community for the purpose of entering into licensing agreements.
| Jeff MorhetChairman/CEO | Angela GiannoccaroChief Financial Officer |
| Jur StrobosChief Medical Officer | Thomas KindtChief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
IHE News
-
Industry News
No stories found
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page